Effect of Citalopram on Three Months Functional Prognosis of Acute Ischemic Stroke Patients

Phase 2

• Conditions: Ischemic stroke.; Cerebral infarction

• Registration Number: IRCT201203192150N2
• Lead Sponsor: eurosciences Research Center

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 144

Inclusion Criteria

1- Acute ischemic stroke hospitalization in Razi university hospital; 2- No previous use of citalopram and other antidepressants, MAOI, Neuroleptic drugs and benzodiazepines in the last month before the onset of symptoms; 3- Not having a severe disability after stroke(NIHSS<20); 4-Not having Depression(MADRS>18). Exclusion criteria: 1- Request of patients to Exit from the study; 2- Previous chronic disease interferes with the performance evaluation in patients such as: chronic infections, liver or kidney failure, cancers; 3- Residual weakness of previous stroke; 4- Pregnancy or breastfeeding or any conditions that makes follow up impossible; 5- Sever loss of Consciousness; 6- Thrombolytic therapy; 7-Endarterectomy; 8- Depression(MADRS>18).

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Functional status after stroke. Timepoint: At hospitalization(0), discharge(1), and after 3 months(2). Method of measurement: Functional status score based on NIHSS(National institutes of health stroke scale)(at least 50% reduction in NIHSS score in 3-month compared to the baseline score.

Secondary Outcome Measures

Name	Time	Method
Prognosis after stroke. Timepoint: At hospitalization(0), discharge(1), and after 3 months(2). Method of measurement: Modifi ed Rankin scale (MRS).